The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

Share Price Information for Beximco Pharma (BXP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 36.50
Bid: 35.00
Ask: 38.00
Change: 0.00 (0.00%)
Spread: 3.00 (8.571%)
Open: 37.50
High: 37.50
Low: 36.50
Prev. Close: 36.50
BXP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of Preliminary Results and AGM

1 May 2013 07:00

RNS Number : 6819D
Beximco Pharmaceuticals Ltd
01 May 2013
 



BEXIMCO PHARMACEUTICALS LTD.

 

1th May, 2013

 

Notification of Preliminary Results and Annual General Meeting

 

Beximco Pharmaceuticals Ltd. ("BPL" or "Company": AIM Symbol: BXP) today announces information for the shareholders of the Company that the Board of Directors at their meeting held on 30th April, 2013 has decided the following:

 

 

1.

To recommend the approval of the Financial Statements for the year ended 31 December 2012

:

The Audited Financial Statements for the year ended 31 December 2012 has been approved. The full accounts are expected to be announced by 15th May 2013

2.

Date & Time of 37th AGM of the Company for the year 2012

:

29 June, 2013 at 10.00 am

3.

Venue of AGM

:

Beximco Industrial Park, Sarabo, Kashimpur, Gazipur, Bangladesh

4.

Proposed Dividend for the year ended 31 December 2012

:

15% Stock Dividend (i.e. 15 shares for every 100 shares held)

5.

Record date

:

20 May, 2013

6.

Net Asset Value as at 31 December 2012

:

Taka 18,408,161,859

7.

Net Asset Value per Share as at 31 December 2012

:

Taka 60.43

8.

Earnings per share (EPS) for the year ended 31 December 2012

:

Taka 4.33

9.

Net Operating Cash Flow per share for the year ended 31 December 2012

:

Taka 6.10

 

 

For further information please visit www.beximco-pharma.com or enquire to:

 

Beximco Pharma

Nazmul Hassan MP, Managing DirectorTel: +880 2 861 9151, ext.20080

 

Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel; +880 2 8618220-1, Ext 10140

 

Libertas Capital Corporate Finance (Nomad)

Thilo Hoffmann

Tel: +44 (0)20 7569 9650

 

Daniel Stewart & Company (Broker)

Paul Shackleton

James Thomas

Tel: +44 (0)20 7776 6550

 

FTI Consulting

Simon Conway / Susan Stuart / Victoria Foster-MitchellTel: +44 (0)20 7269 7169

 

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions etc. Ensuring access to quality medicines is the powerful aspiration that motivates 2,700 employees of the Company.

 

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, Gulf nations, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island and Latin & Central American countries, Middle East and South East Asia, including Singapore, Malaysia, Philippines and Hong Kong.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCURUBROSASOAR
Date   Source Headline
30th Apr 20247:00 amRNSQ3 Financial Results
4th Mar 20247:00 amRNSAppointment of Managing Director
30th Jan 20247:00 amRNSHalf Year Results 2023-24
25th Jan 20249:53 amRNSPayment of Cash Dividend
11th Jan 202411:44 amRNSBoard Change
28th Dec 20239:40 amRNSAGM Statement
6th Nov 202312:17 pmRNSNotice of AGM
6th Nov 20237:00 amRNSFinancial Results for the First Quarter
1st Nov 20237:00 amRNSResults for the year ended 30 June 2023
20th Oct 20237:00 amRNSNotification of Preliminary Results and AGM
11th Sep 202310:17 amRNSClarification on Press Report
31st Aug 20233:51 pmRNSRe-appointment of Independent Director
2nd May 20237:00 amRNSQ3 Financial Results
11th Apr 20233:59 pmRNSHoldings in Company
31st Mar 202311:03 amRNSHoldings in Company
30th Jan 20237:00 amRNSHalf Year Results 2022-23
19th Jan 20237:00 amRNSPayment of Cash Dividend
23rd Dec 20227:00 amRNSAnnual General Meeting Statement
29th Nov 20222:06 pmRNSSecond Price Monitoring Extn
29th Nov 20222:00 pmRNSPrice Monitoring Extension
16th Nov 20227:00 amRNSAGM Notification
11th Nov 20227:00 amRNSFinancial Results for the First Quarter
8th Nov 20227:00 amRNSResults for the 12-month period ended 30 June 2022
28th Oct 20227:00 amRNSNotification of Preliminary Results and AGM
28th Apr 20227:00 amRNSQ3 Financial Results
1st Apr 20227:00 amRNSSanofi Bangladesh Ltd. renamed Synovia Pharma PLC
17th Mar 20222:30 pmRNSMPP sub-license for Pfizer’s COVID-19 treatment
28th Jan 20227:00 amRNSHalf Year Results 2021-22
21st Jan 20227:00 amRNSPayment of Cash Dividend
20th Jan 20229:00 amRNSLicense to produce molnupiravir for COVID-19
30th Dec 202110:38 amRNSWorld's first generic version of Pfizer’s Paxlovid
24th Dec 20217:00 amRNSAnnual General Meeting Statement
8th Dec 20217:00 amRNSDelivery of COVID-19 vaccine doses
2nd Dec 20217:00 amRNSUpdate on the supply of COVID-19 vaccine
24th Nov 20217:43 amRNSStatement re: media comment
16th Nov 20217:00 amRNSNotice of AGM
11th Nov 202110:30 amRNSResults for First Quarter Ended 30 September 2021
9th Nov 20217:00 amRNSLaunch of world’s first generic molnupiravir
2nd Nov 20217:00 amRNSResults for the year ended 30 June 2021
21st Oct 202112:36 pmRNSNotification of Preliminary Results and AGM
11th Oct 20217:00 amRNSUpdate on the supply of COVID-19 vaccine
1st Oct 20217:00 amRNSCompletion of Sanofi Bangladesh Acquisition
14th Sep 202110:20 amRNSSanofi Bangladesh Share Purchase Agreement signed
3rd Sep 20211:10 pmRNSAcquisition Approved by Bangladesh Bank
25th Aug 20216:01 pmRNSStatement re: media comment
26th Jul 20217:00 amRNSFDA approval for muscle relaxant drug Baclofen
7th Jul 20212:23 pmRNSUpdate on the supply of COVID-19 vaccine
30th Apr 20217:00 amRNSQ3 Financial Results
28th Apr 20217:00 amRNSUpdate on the supply of COVID-19 vaccine
24th Mar 20214:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.